Key result
Compound X1 reverses multidrug resistance and reduces glutathione S-transferase in doxorubicin-resistant carcinoma cells.
Why the study?
Multidrug resistance in doxorubicin-resistant Ehrlich ascites carcinoma cells is associated with elevated glutathione and glutathione S-transferase levels, and strategies to reverse this resistance are needed.
Oxalyl bis(N-phenyl)hydroxamic acid (X1) demonstrates potential in reversing doxorubicin-induced multidrug resistance in vitro.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for X1 in doxorubicin-resistant cancers; prospective validation required before clinical consideration.
Choudhuri et al. (1998) studied Ehrlich ascites carcinoma / Multidrug resistance. Oxalyl bis(N-phenyl)hydroxamic acid (X1) vs. Succinyl bis(N-phenyl)hydroxamic acid (X2) / Drug-sensitive cells was evaluated on Reversal of multidrug resistance and reduction of glutathione S-transferase (GST). The compound oxalyl bis(N-phenyl)hydroxamic acid (X1) was able to reverse the effect of multidrug resistance and reduce glutathione S-transferase in doxorubicin-resistant carcinoma cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: